Figure 1.

Prevalence of sulphadoxine-pyrimethamine (SP) treatment failure and molecular markers of resistance to SP at five sites in Tanzania. Ratios of prevalence of the DHFR triple mutant to SP treatment failure ranged from 2.0 to 2.1 at four of the five sites where SP resistance was low or moderate, suggesting that this molecular marker could serve as a reliable surrogate for SP efficacy at these sites. Adapted from [12] with permission.